According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.
Recent News
ProFactor Pharma (PFP) realise further capital injection – August 2022
ProFactor Pharma is pleased to announce completion of a further investment round. The investment will enable PFP to progress the company’s clinical stage Recombinant Human Factor VIII to market and to engage with commercial licensing opportunities. The funding...
Health Tech World – Interview – Ending the Haemophilia Drug Shortage (23 November 2021)
Published on November 23, 2021 By Deborah Johnson https://www.htworld.co.uk/news/ending-haemophilia-drug-shortage/ Jaymin Amin, CEO of ProFactor Pharma (PFP), discusses the company’s life-changing, and lifesaving, work. PFP says it has developed a low-cost production...